Tandem Diabetes Care Inc. (NASDAQ:TNDM) was up 5.9% during trading on Monday . The company traded as high as $6.98 and last traded at $6.95, with a volume of 243,035 shares trading hands. The stock had previously closed at $6.56.

A number of equities research analysts have recently commented on TNDM shares. Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Tandem Diabetes Care in a report on Friday, July 29th. Sterne Agee CRT reissued a “neutral” rating on shares of Tandem Diabetes Care in a report on Monday, May 16th. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Wednesday, July 6th. Piper Jaffray Cos. reissued a “buy” rating and set a $12.00 price target on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Finally, Robert W. Baird reissued a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Tandem Diabetes Care currently has a consensus rating of “Hold” and an average price target of $14.21.

The firm has a 50-day moving average of $7.42 and a 200 day moving average of $8.12. The company’s market cap is $208.47 million.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.60) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.05. The company had revenue of $23 million for the quarter, compared to analyst estimates of $23.08 million. During the same period in the prior year, the business earned ($0.65) earnings per share. Tandem Diabetes Care’s revenue was up 46.5% on a year-over-year basis. Equities research analysts anticipate that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current fiscal year.

In other Tandem Diabetes Care news, EVP John F. Sheridan sold 15,000 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $6.52, for a total transaction of $97,800.00. Following the completion of the transaction, the executive vice president now directly owns 22,763 shares of the company’s stock, valued at approximately $148,414.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Tandem Diabetes Care stock. Westfield Capital Management Co. LP raised its stake in shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,125,281 shares of the medical device company’s stock after buying an additional 35,680 shares during the period. Westfield Capital Management Co. LP owned about 3.74% of Tandem Diabetes Care worth $13,290,000 as of its most recent filing with the SEC.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.